Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2022-11-11
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 783074 NOK
Award criteria: Lowest price

Technical requirements: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for parenteral special pharmaceutical preparations (LIS 2201c). The contest includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List. No tenders were received for this active ingredient.
After the contest, tenders were received for the products listed in the annexes to this notice, where the supplier must have a marketing licence. See the Medicines Act §8 and the Medicine Regulations §2-1, first and second sections, in which, as a main rule, a marketing licence is required before a medicine can be sold. There were no other tenders in this contest for the relevant sub-delivery (sub-delivery 199, ATC code N01AH03, Sufentanil, injection fluid).
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for parenteral special pharmaceutical preparations (LIS 2201c). The contest includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List. No tenders were received for this active ingredient.
After the contest, tenders were received for the products listed in the annexes to this notice, where the supplier must have a marketing licence. See the Medicines Act §8 and the Medicine Regulations §2-1, first and second sections, in which, as a main rule, a marketing licence is required before a medicine can be sold. There were no other tenders in this contest for the relevant sub-delivery (sub-delivery 199, ATC code N01AH03, Sufentanil, injection fluid).
Due to this, Sykehusinnkjøp intends to enter into contracts between the regional health authorities (the Contracting Authorities) and Biocodex AS (the Supplier) as an additional contract to LIS 2201c, i.e., the scope and length of the contract must follow the mentioned procurement (including access to extensions and terminations), without a new contest being held for this active substance. The health trusts that are under the regional health authorities have an option to enter the agreements. The same applies to non-profit institutions/hospitals with an operational contract with an individual health region.
Sykehusinnkjøp has explored the market situation and is of the opinion that it is impossible to hold a new contest, or that a supplier other than Biocodex AS is able to deliver the product in the impending contract period, and that the situation that has occurred is not the contracting authorities' fault, nor something that the contracting authorities could predict. Sykehusinnkjøp therefore believes that there are grounds to carry out the procurement without a contest. See the public procurement regulations §21-5, c.f. § 21-2, c.f. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.
LIS requests that any objections to this contract award are submitted before the expiry of the waiting period, set to 10 days after the publication of the Voluntary ex ante transparency notice. If no objections are received, contracts will be signed after the waiting period has expired.
Sykehusinnkjøp has explored the market situation and is of the opinion that it is impossible to hold a new contest, or that a supplier other than Biocodex AS is able to deliver the product in the impending contract period, and that the situation that has occurred is not the contracting authorities' fault, nor something that the contracting authorities could predict. Sykehusinnkjøp therefore believes that there are grounds to carry out the procurement without a contest. See the public procurement regulations §21-5, c.f. § 21-2, c.f. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.


Winner: Biocodex AS
Award value: 783074